This study aims to determine the effect of online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. The sample size was calculated using the 'G. Power-3.1.9.2' programme at a 95% confidence level prior to data collection. Accordingly, the minimum sample size required for the independent sample t-test for the study was determined to be 44 (22 for each group) based on an alpha value of 0.05, an effect size of 1.128, and a theoretical power of 95%. Taking data losses into account, a total of 60 patients (30 for each group) were planned to be included in the sample. Data will be collected using the Heart Failure Symptom Status Scale, Medication Adherence and Prescription Printing Scale (İURYÖ-7), Heart Failure Nutrition Behaviour Scale. 1: Prior to providing education to patients, they will be informed about the purpose of the study, the data collection method, and the topics to be covered in the education. Patients who agree to participate in the study will be asked to sign an informed consent form. All patients in the experimental and control groups will be asked to complete the Heart Failure Nutrition Behaviour Scale (HFNBS), Heart Failure Symptom Status Scale (HFSSS), and Medication Adherence and Prescription Writing Scale (MAPWS-79) before receiving education.
2: The contact information of all patients in the experimental group will be collected. Training will be provided online at a time and date convenient for the patients.
3: Patients in the control group will receive a digital training booklet prepared by the researcher at the contact address they provide.
4: Participants will be contacted 2 weeks, 1 month, and 2 months after the initial education session to obtain feedback on post-education dietary behaviours, medication adherence, and symptoms.
5: Four to six weeks after the training is completed, the 'Nutritional Behaviour Scale in Heart Failure,' 'Heart Failure Symptom Status Scale,' and 'Medication Adherence and Prescription Writing Scale (İURYÖ-7)' will be completed online again. The same forms will also be completed online by patients in the control group 4-6 weeks later.

开始日期2025-07-15

申办/合作机构

Canakkale Onsekiz Mart University

NCT06536309

/ Not yet recruiting临床4期IIT

Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

Cardiac magnetic resonance imaging (MRI) measures of myocardial interstitial fibrosis (MIF) are elevated in heart failure with preserved ejection fraction (HFpEF) patients and associated with poor prognosis. Extracellular volume (ECV) is the most reproducible and best validated cardiac MRI measure of MIF. Sacubitril/valsartan reduces histological MIF in mice and levels of some extracellular matrix regulatory proteins in humans with HFpEF. However, the effect of sacubitril/valsartan on robust measures of MIF in humans is unknown. Demonstrating reductions in ECV with sacubitril/valsartan would clarify the mechanism of this approved medication. Given the borderline reduction in heart failure hospitalizations with sacubitril/valsartan and the heterogeneity of HFpEF pathophysiology, this result would suggest that neprilysin inhibition may particularly benefit HFpEF patients with greater MIF. The investigators propose a proof-of-concept clinical trial to evaluate the effect of neprilysin inhibition (sacubitril/valsartan vs valsartan alone) on cardiac MRI measures of fibrosis (principally ECV) and circulating protein levels.

开始日期2025-07-01

申办/合作机构

The Brigham & Women's Hospital, Inc.

CTR20251477

/ RecruitingN/A

沙库巴曲缬沙坦钠片在健康受试者中的单剂量、随机、开放、完全重复交叉、两制剂、四周期空腹及餐后人体生物等效性试验

以四川依科制药有限公司的沙库巴曲缬沙坦钠片（规格：200mg，其中沙库巴曲97mg/缬沙坦103mg）为受试制剂，以Novartis Pharma Schweiz AG的沙库巴曲缬沙坦钠片（规格：200mg，其中沙库巴曲97mg/缬沙坦103mg）为参比制剂，按生物等效性试验的有关规定，考察两制剂在健康人体内的生物等效性。

开始日期2025-05-11

申办/合作机构

四川依科制药有限公司

100 项与沙库巴曲缬沙坦钠相关的临床结果

登录后查看更多信息

100 项与沙库巴曲缬沙坦钠相关的转化医学

登录后查看更多信息

100 项与沙库巴曲缬沙坦钠相关的专利（医药）

登录后查看更多信息

672

项与沙库巴曲缬沙坦钠相关的文献（医药）

2025-09-01·HEART & LUNG

Clinical outcomes of sacubitril-valsartan versus angiotensin converting enzyme inhibitor or angiotensin receptor blocker among patients with heart failure and ejection fraction at/less than 60 %: A retrospective, observational, parallel cohort, multi-group study

Article

作者: Bena, James F ; Albert, Nancy M ; Martyn, Trejeeve ; Khairnar, Rahul ; Faulkenberg, Kathleen ; Morrison, Shannon L ; Williams, J Bradley

BACKGROUND:

Real-world heart failure (HF) and all-cause hospitalization, HF-related emergency care visits, all-cause mortality and the composite of all-cause or HF hospitalization or HF-related emergency visit remain high, due to underuse of core HF medications.

OBJECTIVES:

A better understanding of real-world clinical outcomes is needed based on sacubitril-valsartan vs. angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) use among patients with HF and a wide range of ejection fractions.

METHODS:

Data retrieved from a multi-center, multi-state healthcare system database of patients prescribed sacubitril-valsartan were matched to those on ACEI/ARB based on age, sex, EF, comorbidity status, systolic blood pressure and index date site (hospital or ambulatory). Six- and 12-month outcomes based on sacubitril-valsartan vs. ACEI/ARB were assessed using linear, logistic, and Poisson models with generalized estimating equations.

RESULTS:

Patients (N = 4188; 2094/cohort) were well matched based on characteristics; 29.8 % were female, mean (SD) age was 64.3 (13.1) years, systolic blood pressure was 122.0 (16.2) mmHg, EF% was 29.1 (9.9); nearly half were in NYHA FC II and 422 (10.1 %) had EF of 41-60 %. Frequency of non-study medications at baseline was 92.6 % beta-blocker, 43.2 % mineralocorticoid receptor antagonist and 64.2 % loop diuretic. Compared to ACEI/ARB, all 6 and 12-month clinical outcomes were improved among patients using sacubitril-valsartan (all 12-month p<.001).

CONCLUSIONS:

Among patients with HF and EF up to 60 %, sacubitril-valsartan use was associated with lower 12-month morbidity and mortality. Providers and clinicians need to advocate for use of sacubitril-valsartan per hierarchical renin angiotensin system inhibitor national guideline recommendations.

2025-08-01·JACC-Heart Failure

Effect of Neprilysin Inhibition on Plasma Proteins in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Article

作者: Chutkow, William ; Zhang, Luqing ; Cunningham, Jonathan W ; Marti-Castellote, Pablo M ; Claggett, Brian L ; Zile, Michael R ; Yates, Denise ; McMurray, John J V ; Solomon, Scott D ; Mendelson, Michael M

2025-07-01·ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE

The Efficacy of Sacubitril Valsartan Sodium in Combination with Levosimendan in the Treatment of Cardiorenal Syndrome and the Effect on Cardiac and Renal Function.

Article

作者: Zhang, Huaan ; Ren, Weirong ; Chen, Zhiheng ; Ye, Yuchang

Objective:

To investigate the effects of sacubitril valsartan sodium combined with levosimendan on improving cardiac and renal functions in patients with CRS.

Methods:

90 patients with the cardiorenal syndrome who were hospitalized in our hospital from February 2020 to February 2022 were selected and divided into two groups, the control group, and the joint group, according to both single and double number methods, with 45 cases in each group. Patients who met the diagnostic criteria for CRS, were older than 18 years of age, had NYHA class II to IV, and had stage 1 or 2 chronic kidney disease were included in the study. Patients with severe hypersensitivity to the drugs used in this test, haemodynamic instability, combined hyperthyroidism, malignancy, severe pulmonary hypertension, cardiogenic shock, malignant arrhythmias and pregnant women were excluded. Among them, the control group was treated with sacubitril valsartan sodium alone, and the joint group was treated with levosimendan supplemented with the treatment method of the control group. The treatment effect, the improvement of cardiac and renal function, and the incidence of adverse reactions were compared between the two groups of CRS patients, and the prognostic effect was followed up 6 months after treatment.

Results:

The total effective rate of treatment in the joint group was 95.56%, which was significantly higher than that in the control group of 80.00%, and the difference was statistically significant by using χ2 test (P < .05). After treatment, LVEF, LVEDD, and NT-proBNP levels in both groups were significantly improved compared with those before treatment (P < .05), and the improvement effect of each index in the joint group was more significant than that in the control group (P < .05). After treatment, the levels of SCr, BUN, and UA in both groups were significantly lower than those before treatment (P < .05), and the levels of each index in the joint group were significantly lower than those in the control group, statistical analyses showed significant differences (P < .05) using t test. The incidence of adverse effects such as tachycardia, premature ventricular contractions, heart failure, and myocardial ischaemia was 22.22% in the combined group, which was significantly lower than 42.22% in the control group, and the difference in the total incidence between the two groups was statistically significant by χ2 test (P < .05). One case of malignant arrhythmia and five cases of recurrence of heart failure occurred 6 months after surgery in the combined group, which were significantly lower than the eight and twelve cases in the control group.

Conclusion:

Sacubitril valsartan sodium combined with levosimendan can significantly improve the therapeutic effect of CRS, with significant improvement in cardiac and renal function of CRS patients, and its incidence of adverse effects and long-term prognostic effects are lower than those of sacubitril valsartan sodium alone. This combination therapy offers a promising new direction for CRS management, warranting further investigation in larger, multicenter trials.

871

项与沙库巴曲缬沙坦钠相关的新闻（医药）

2025-06-24

·医药云端工作室

第11批国采、第4批中成药集采品种思考

↑↑↑再战县域，紧扣准入、锁定渠道剖析集采、定价策略欢迎来昆明参会文：点苍鹤集采进入常态化、制度化轨道，有两条主线是相互交织的，一条是政策线，顶层定调定方向定机制，政策制定层定目标定规则，另一条则是产品线，哪些品种按什么样的方式纳入集采。政策线与产品线相互交织，互为因果。企业的政务较为关注，需要理解医疗卫生体制的特点及发展逻辑，说起来宏观，但这是政策落地的核心驱动力。不过，对于行业从业者，特别是一线销售人员，更多关心的产品层面，毕竟某个产品是否进入集采，都很自己的切身利益相关。哪些产品纳入集采？范围多大？什么节奏执行？从一个中长期的项目来说是需要规划的，于是2020年有500产品目录之说，之后还有620、850、184目录（鼓励地方集采的集采空白大额品种）。“出台”这些目录的目的，就是从存量的产品中，根据其占用的医保资金情况，层层筛选，也就是所谓的“拉网式”、“填空式”逐步纳入集采，不断从价格、使用和支付上做到有效管理。但是，业内人士如果只知道做填空题肯定是不够的，不管500目录，还是850目录，都只是阶段性的规划，如果认定这些品种都集采完，集采就不再推行了，那就只能呵呵了。从2024年5月20日医保集采8号文起，集采的目标和节奏就非常清晰，国采层面每年1-2批次，依然还是主攻化学药，其他药品类别的国采，中成药由湖北，中药饮片/配方颗粒通过山东牵头，2025年确定安徽牵头生物药集采；国采接续主要由广东、上海、河南大省协同牵头组织实施；三明联盟的“六病共管”药品耗材集采。2024年，除了国采可替代集采尚未启动外，其余集采项目均在当年11-12月份有了中选结果，并于2025年4月份开始陆续在各省执行。因此，进入6月份之后，2025年的集采任务需要提到议事日程上来，包括：第11批国家集采、第四批全国中成药、全国首批生物药（暂且这么称呼）。第11批国采是今年医保工作重点任务，确定上半年启动，因此，并不怀疑6月份会有相关的政策或消息浮出水面，比如上周末（20日）业内流传的征求意见稿函件及75个品种名单。但需要注意的是，此中存疑多多，不仅仅14个品种适应症、临床使用高风险问题，需要卫健委来评估，另外的品种因涉及专利因素，并不见得75个或其余61个品种都会纳入第11批集采。沙库巴曲缬沙坦口服常释剂型（专利期至2026年11月）伏诺拉生口服常释剂型（专利期至2026年8月）吲哚布芬口服常释剂型（专利期至2040年）达格列净（专利期至2027年06月21日）然而，即便某些品种有争议，但换个角度想，其实是给相关厂家一个提醒，有专利问题的品种，今年不集采，明年呢？专利到期呢？一定会集采！有这样那样原因的品种，换个思路，即便不集采，是否打开政策工具箱，换个工具？只要能够降低价格、合理使用，不见得就一定要通过集采来实现。实施了一年多的价格治理，不就是通过价格管理方式，实现了价差较大、价格有水分的品种的治理吗？这一波下来，直接解决了“老药新作”“改头换面”“价格异常”等问题，也结合信用评价机制，间接解决或部分解决价格虚高背后的销售费用、回扣等长期存在的顽疾。另据消息，湖北牵头第四批全国中成药集采也会在近期推出，而安徽牵头的生物药集采一直没有下文，但据消息称也将在下半年出台政策并实施。第四批中成药会纳入哪些品种？有迹可循的范围，似乎可以从184目录中的91个中成药，可以看到一些端倪。（详见文末表格）从医保资金的占用维度看， 91个中成药都在2亿元之上，销量都不小，是控费的首选品种。从结构来看，91个中成药中有72个独家品种，这个就存在政策和技术问题了。在政策层面，是否由湖北全部集采？（一次性或多批次）。在技术层面，如何对独家品种设定规则？考虑到之前同方异名品种是按组分或处方来分组，那么这72个品种的分类还存在很多问题，比如类别太多不好一次性解决分类/合并问题。因此，个人猜测，这些品种不一定都会放在同一批次内集采。从竞争格局看，除了72个独家、2个9家之外，其余品种的生产企业数量都很多，都达到了数十个甚至384个（板蓝根颗粒）。这些品种，不一定都在医疗机构使用，比如板蓝根颗粒、鲜竹沥、云南白药、摩罗丹、健胃消食等，有的本来就是OTC，在零售药店及电商平台的销量很大。考虑到使用终端的结构性差异，纳入集采不见得是效果最好的治理方式。但与第11批集采的75个品种清单不一样的是，前者已经看到成文的函件出现，但中成药集采名单目前属于猜测阶段。因此，产品层面的话题固然很“接地气”，看上去很爽，但仅仅停留在分析或猜测是不够的，很多复杂的问题，并不是通过一个客户，一条“消息”，一份“名单”就能解决。更多信息及策略，可参加7月12-13日昆明公开课，把握政策脉动、决胜2025下半场 ↓↓↓或者两天课程联报，更多精彩，更多期待↓↓↓关注公众号，获取可靠、专业的资讯和分析内容

2025-06-23

·药通社

废标重选？第十一批拟国采品种分析

这两天，最大的事情莫过于业内流传的第十一批国采拟采购药品清单（涉及75个品种）。据该文件内所写，目前拟采购的75个品种之中，有14个品种还须进行研判。这14个品种分两类：第一类是仿制药适应症少于原研药的，共5个品种，分别是达格列净片、艾曲泊帕乙醇胺片、阿伐曲泊帕口服常释剂型、奥拉帕利片和乙磺酸尼达尼布软胶囊。第二类是专家认为临床使用风险相对较高的，共9个品种，分别是万古霉素注射剂、头孢他啶阿维巴坦注射剂、麦考酚钠口服常释剂型、甲氨蝶呤注射剂、阿糖胞苷注射剂、碘普罗胺注射剂、拉莫三嗪口服常释剂型、曲普瑞林注射剂(0.1mg)、西曲瑞克注射剂。这14个品种仍存在不确定性，须等待进一步研判结果。再分析其他拟采购的品种，首先有一个废标重选品种：盐酸溴己新注射液。该品种第七批集采已集采，经串标被查后废标，现又重新被纳入十一批国采。截至3月31日（网传十一批国采遴选关门时间），盐酸溴己新注射液共15家企业过评，除6家禁标企业外，还有9家企业过评，可参与此次竞标。值得注意的是，按处罚时间来看，仁合益康、广州一品红、石家庄四药三家公司已过处罚期（截至2025年2月），理论上也可参与此次竞标。而剩下三家成都欣捷、上海旭东海普、江西亿友禁标时间仍未到，不可参与此次竞标。另外，目前目录内存在专利未到期品种，包括沙库巴曲缬沙坦口服常释剂型（专利期至2026年11月）、伏诺拉生口服常释剂型（专利期至2026年8月）、吲哚布芬口服常释剂型（专利期至2040年）。尤其是吲哚布芬口服常释剂型，中美华东强势的专利要求已经使得多家企业暂停挂网，浙江美迪深、浙江同伍、湖南九典三家均已撤网。这三个有专利限制的品种，最终或被剔除。此前药通社进行过统计，截至6月下旬，已有149个品种满足十一批国采要求（≥7家）的要求。详见：十一批国采首个！超40家！将该目录与此次拟纳入的75个品种进行对比，除去截止3月末不满足≥7家的31个品种，还剩下45个品种符合过评竞争企业数要求，但未被纳入。这45个品种未被纳入的原因是什么？首先是由于“新老文号交叉”。简单解释一下。2023年8月23日，国家组织药品联合采购办公室曾发布一份说明文件，对于口服固体制剂和注射剂以外的剂型（口服溶液、吸入剂、滴眼液等）既有老批件又有新批件的产品暂不列入本次集采。此份说明原本只限于第八批国采，但实际上第九批和第十批集采大部分品种也在遵循此原则。这一次很多品种也存在这种情况（详见下表），大概率也是因为这个原因而未被纳入。这里面包括很多大品种——如18亿市场的乳果糖口服液体剂（33+1）、30亿市场的乙酰半胱氨酸吸入剂（28+1）等。但也并非所有新老批件交叉的品种都不纳入，比如这次纳入的地氯雷他定口服制剂被纳入，该品种就存在老文号未过评情况。第二个主要原因就是临床需求太小。比如ω-3脂肪酸乙酯90口服常释剂型、利托那韦口服常释剂型等目前市场还不到百万。除此之外，还涉及到剂型的问题。截止目前还没有乳膏和洗剂之类纳入国采，此次也有很多乳膏满足要求，但均未被纳入。还有一些就是条件全都符合但就是未被纳入的品种，比如他氟前列素滴眼剂市场上亿，过评8家，全是新批件。像这种的品种，其实每一批都有，只是还未轮到。8 月 1-2 日，“仿制药和改良新药立项‘稳准狠’大会”，苏州开幕！风云药谈创始人张廷杰现场解析《新集采（11 批）、大接续、价格治理下的产品布局》，线下直击政策红利期的立项策略，速抢席位共探行业破局点。CMC制药工业博览会附表一：3月31号满足竞争≥7家，但未被纳入的45个品种附表二：第十一批国采拟采购的75个品种↓ 关注药通社，洞见行业趋势 ↓投稿/企业合作/内容沟通：华籍美人（Ww_150525）

专利到期带量采购

2025-06-21

·药筛

74个产品销售数据排名，最高近50亿，最低不足1亿元

大家关心的75个品种，实际是74个，其中序号62和63的产品充分，都是复方电解质注射剂。我统计了各品种2024年医院市场销售规模，达格列净以49亿元排名第一，沙库巴曲缬沙坦以43.6亿排名第二。最少的是丙卡特罗吸入剂，只有0.4亿；头孢丙烯口服液体剂等几个品种，也不足亿元。优化方案中，说好的市场规模小的品种，暂不考虑，难道1亿元也算不小？哎，目录真是个玄学啊！以下是产品销售额排名，数据来自摩熵医药全终端药品销售数据。产品名称2024年销售额（亿元）过评企业数达格列净口服常释剂型4924沙库巴曲缬沙坦口服常释剂型43.622头孢唑肟注射剂36.232福莫特罗吸入剂35.815奥司他韦颗粒剂34.28罗沙司他口服常释剂型24.516亚胺培南西司他丁注射剂23.27万古霉素注射剂19.87法莫替丁注射剂18.729碘普罗胺注射剂18.78吲哚布芬口服常释剂型18.613洛索洛芬贴剂18.47溴己新注射剂16.315苯唑西林注射剂13.57头孢他啶阿维巴坦注射剂12.113奥拉帕利口服常释剂型129麦考酚钠口服常释剂型10.510复方醋酸钠林格注射剂9.18阿戈美拉汀口服常释剂型815伏诺拉生口服常释剂型7.812腺苷蛋氨酸注射剂7.59帕利哌酮缓释控释剂型7.47多巴丝肼口服常释剂型78瑞巴派特口服常释剂型6.713贝尼地平口服常释剂型6.57二羟丙茶碱注射剂6.530尼可地尔口服常释剂型6.412普伐他汀口服常释剂型6.28贝前列素口服常释剂型6.29厄他培南注射剂6.27倍他米松注射剂6.19地诺孕素口服常释剂型6.111氟伏沙明口服常释剂型5.515福沙匹坦双葡甲胺注射剂5.47恩扎卢胺口服常释剂型5.29右丙亚胺(右雷佐生)注射剂5.27碳酸氢钠注射剂515阿伐曲泊帕口服常释剂型4.816中/长链脂肪乳(C6-24)注射剂4.67复方电解质注射剂4.58拉莫三嗪口服常释剂型4.58艾曲泊帕乙醇胺口服常释剂型4.412阿瑞匹坦口服常释剂型4.27奥卡西平口服常释剂型47尼达尼布口服常释剂型47艾多沙班口服常释剂型3.99阿仑膦酸口服常释剂型3.78尼麦角林口服常释剂型3.49布比卡因注射剂3.28二甲双胍恩格列净口服常释剂型3.112腺苷钴胺口服常释剂型3.112阿糖胞苷注射剂3.18替考拉宁注射剂3.110地氯雷他定口服液体剂324卢帕他定口服常释剂型2.711西曲瑞克注射剂2.78硫酸镁钠钾口服用浓溶液2.617氯诺昔康注射剂2.517甲氨蝶呤注射剂2.410西洛他唑口服常释剂型2.17钆布醇注射剂27阿莫西林克拉维酸口服液体剂27吡拉西坦(乙酰胺吡咯烷酮)口服常释剂型28阿格列汀口服常释剂型1.916美索巴莫注射剂1.812沙丁胺醇注射剂1.88肾上腺素注射剂1.77异烟肼注射剂1.67去氧肾上腺素注射剂1.514曲普瑞林注射剂(0.1mg)1.48维库溴铵注射剂1.27甲氧氯普胺注射剂18头孢丙烯口服液体剂17丙卡特罗吸入剂0.48用摩熵药筛小程序，快速查询产品市场销售数据！

临床研究临床结果

100 项与沙库巴曲缬沙坦钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C09DX04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
原发性高血压	中国	Novartis Pharma Schweiz AG	2021-05-24
高血压	日本	Novartis Pharma KK	2020-06-29
左心室收缩功能障碍	美国	Novartis Pharmaceuticals Corp.	2019-10-01
射血分数降低的慢性心力衰竭	欧盟	Novartis Europharm Ltd.	2015-11-19
射血分数降低的慢性心力衰竭	冰岛	Novartis Europharm Ltd.	2015-11-19
射血分数降低的慢性心力衰竭	列支敦士登	Novartis Europharm Ltd.	2015-11-19
射血分数降低的慢性心力衰竭	挪威	Novartis Europharm Ltd.	2015-11-19
心脏衰竭	瑞士	Novartis AG	2015-09-17
慢性心力衰竭	美国	Novartis Pharmaceuticals Corp.	2015-07-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床3期	美国	Chong Kun Dang Pharmaceutical Corp.	2024-10-14
心肌梗塞后综合征	临床3期	-	Novartis Pharmaceuticals Corp.	2021-05-26
勃起功能障碍	临床3期	德国	Novartis Pharmaceuticals Canada, Inc.	2019-04-16
收缩性心力衰竭	临床3期	德国	Novartis Pharmaceuticals Canada, Inc.	2019-04-16
急性心肌梗塞	临床3期	美国	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	中国	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2016-12-09
急性心肌梗塞	临床3期	比利时	Novartis Pharmaceuticals Corp.	2016-12-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


PARADIGM-HF and PARAGON-HF (Pubmed \| JACC Heart Fail)	N/A	心脏衰竭 N-terminal pro-B type natriuretic peptide (NT-proBNP)	-	Sacubitril/Valsartan	繭襯鑰獵鏇積網簾簾窪(觸廠餘願繭觸衊艱艱憲) = 遞範鏇築範網壓鑰願襯製糧憲憲餘構繭夢觸夢 (艱夢醖積醖築構衊網範, 5.3 ~ 6.5)	积极	2025-06-01
NCT01035255 (PARADIGM-HF, Pubmed \| J Am Heart Assoc)	临床3期	射血分数保留型心力衰竭	8,399	Sacubitril/Valsartan	齋繭鹽選蓋願餘齋衊醖(蓋衊願艱觸蓋艱製鹽願): P-Value = 0.62 更多	积极	2025-05-06
				Enalapril
NCT03988634 (PARAGLIDE-HF, Pubmed \| Am Heart J)	临床3期	射血分数保留型心力衰竭 NT-proBNP \| LVEF	-	Sacubitril/valsartan	齋選蓋糧艱艱網窪蓋憲(廠製窪壓壓齋襯衊鹹衊): rate ratio = 0.6 (95% CI, 0.37 ~ 0.99), P-Value = 0.046 更多	积极	2025-04-01
				Valsartan
ISC2025	N/A	急性缺血性卒中 \| 高血压	-	Sacubitril/Valsartan	構餘夢齋膚艱觸壓鬱鏇(糧夢鑰顧廠鏇鬱積鬱鏇) = No hypotension occurred in either group 膚蓋齋積淵廠膚膚遞夢 (願鹹鬱蓋鏇積餘窪廠範 ) 更多	积极	2025-01-30
				Other antihypertensive agents
NCT01035255 (PARADIGM-HF, Pubmed \| Eur J Heart Fail)	临床3期	射血分数降低的心力衰竭 \| 慢性心力衰竭	8,399	Beta-blocker	鹹衊醖鏇積鏇膚壓繭顧(獵繭廠構廠顧遞製衊構): HR = 0.47 (95% CI, 0.32 ~ 0.69) 更多	积极	2024-11-19
				No Beta-blocker
NCT02678312 (PANORAMA-HF, Pubmed \| Circulation) 人工标引	临床2/3期	心脏衰竭	375	Sacubitril/Valsartan	夢齋觸獵淵衊觸壓網淵(廠網獵願壓廠蓋餘鹽餘): OR = 0.91 (95% CI, 0.72 ~ 1.14), P-Value = 0.42 更多	不佳	2024-09-25
				Enalapril
NCT01920711 (PARAGON-HF, Pubmed \| Eur J Heart Fail)	临床3期	心脏衰竭	4,795	Sacubitril/valsartan	蓋艱鏇製構願襯糧構範(淵簾選淵鏇選醖範願製) = 遞遞衊鏇壓窪鏇選糧夢願膚遞壓願繭齋衊製餘 (願積遞積鑰艱觸繭膚窪, 0.0 ~ 0.2) 更多	积极	2024-09-01
				Valsartan	選蓋構鹹顧鹽夢顧築醖(鑰夢獵遞鏇願簾鏇網膚) = 選廠鬱醖積淵遞繭憲觸鬱觸淵選壓製觸憲選鬱 (願蓋淵蓋糧範窪繭獵夢 ) 更多
ESC2024	N/A	-	24	sacubitril/valsartan (Control)	遞醖範衊齋淵淵遞鏇淵(鬱簾鬱淵廠顧衊觸膚艱) = 鏇簾糧鹽積簾夢糧鑰糧製廠鬱繭襯醖顧繭鹽繭 (膚獵壓簾觸衊鹹夢獵壓 )	不佳	2024-08-31
				Sacubitril/Valsartan	遞醖範衊齋淵淵遞鏇淵(鬱簾鬱淵廠顧衊觸膚艱) = 膚網齋願構簾鬱選築構製廠鬱繭襯醖顧繭鹽繭 (膚獵壓簾觸衊鹹夢獵壓 )
ESC2024	N/A	心脏衰竭	-	Sacubitril/Valsartan (Patients aged below 80 years)	網鹽鬱網醖範廠獵遞憲(膚觸構遞簾觸鹹製鏇鹹) = 積積鏇鑰選蓋願構艱壓鹽艱醖醖膚艱顧廠鏇餘 (膚艱餘顧鬱構遞築壓鑰 )	-	2024-08-31
				Sacubitril/Valsartan (Patients aged above 80 years)	網鹽鬱網醖範廠獵遞憲(膚觸構遞簾觸鹹製鏇鹹) = 獵顧衊窪顧糧餘襯鹹構鹽艱醖醖膚艱顧廠鏇餘 (膚艱餘顧鬱構遞築壓鑰 )
ESC2024	N/A	心脏病	-	ARNI Sacubitril/Valsartan	膚製夢鹽簾膚繭簾範夢(築廠遞鹹壓範蓋廠鹽襯) = 網觸築鹽窪鹹衊餘淵廠襯鬱顧顧鬱觸憲齋選夢 (構糧衊顧築範鹽網蓋簾, 806 ~ 4330)	-	2024-08-31